Tokyo Tape
Sign in
← Taiko Pharmaceutical

Quarterly report · Q1

4574.TEDINET S100TDKT
Period2024-01-01 → 2024-03-31
Filed2024-05-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
MetricValuePeriodScopeSource row
Revenue¥1.4bn2024-01-01 → 2024-03-31Cons.Net sales
Revenue¥6.1bn2023-01-01 → 2023-12-31Cons.Net sales (5-year summary)
Revenue¥1.2bn2023-01-01 → 2023-03-31Cons.Net sales
Operating income¥214m2024-01-01 → 2024-03-31Cons.Operating income
Operating income−¥155m2023-01-01 → 2023-03-31Cons.Operating income
Ordinary income¥229m2024-01-01 → 2024-03-31Cons.Ordinary income
Ordinary income−¥1.2bn2023-01-01 → 2023-12-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥242m2023-01-01 → 2023-03-31Cons.Ordinary income
Profit before tax¥429m2024-01-01 → 2024-03-31Cons.Income before income taxes
Profit before tax−¥242m2023-01-01 → 2023-03-31Cons.Income before income taxes
Net income (owners)¥472m2024-01-01 → 2024-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥3.6bn2023-01-01 → 2023-12-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥243m2023-01-01 → 2023-03-31Cons.Profit loss attributable to owners of parent
Net income¥472m2024-01-01 → 2024-03-31Cons.Profit loss
Net income−¥243m2023-01-01 → 2023-03-31Cons.Profit loss
Total assets¥13.0bnat 2024-03-31Cons.Assets
Total assets¥13.2bnat 2023-12-31Cons.Assets
Total assets¥14.4bnat 2023-03-31Cons.Total assets (5-year summary)
Total liabilities¥5.6bnat 2024-03-31Cons.Liabilities
Total liabilities¥6.5bnat 2023-12-31Cons.Liabilities
Net assets / equity¥7.4bnat 2024-03-31Cons.Net assets
Net assets / equity¥6.7bnat 2023-12-31Cons.Net assets
Net assets / equity¥7.9bnat 2023-03-31Cons.Net assets (5-year summary)
Cash and deposits¥5.2bnat 2024-03-31Cons.Cash and deposits
Cash and deposits¥5.5bnat 2023-12-31Cons.Cash and deposits
EPS (basic)¥9.412024-01-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-76.252023-01-01 → 2023-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-5.592023-01-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
Equity ratio57.1%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio51.0%at 2023-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio54.5%at 2023-03-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 26
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2024-01-01 → 2024-03-31−¥207m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥140m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥140m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2024-01-01 → 2024-03-31−¥64m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2024-01-01 → 2024-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2024-01-01 → 2024-03-31−¥2m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2024-01-01 → 2024-03-31¥1.2bn
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2024-01-01 → 2024-03-31¥1.2bn
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2024-01-01 → 2024-03-31¥489m
Total Of Reportable Segments And Otherssegment totalrevenue2024-01-01 → 2024-03-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-01-01 → 2024-03-31¥1.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-01-01 → 2024-03-31¥421m
Reconciling Itemsreconcilingsegment profit2023-01-01 → 2023-03-31−¥241m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥259m
jpcrp040300-q1r_E22560-000Infection Control Businessreportable segmentsegment profit2023-01-01 → 2023-03-31−¥124m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentrevenue external2023-01-01 → 2023-03-31¥1m
jpcrp040300-q1r_E22560-000Other Business Linesreportable segmentsegment profit2023-01-01 → 2023-03-31−¥5m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentrevenue external2023-01-01 → 2023-03-31¥906m
jpcrp040300-q1r_E22560-000Pharmaceuticals Businessreportable segmentsegment profit2023-01-01 → 2023-03-31¥215m
Total Of Reportable Segments And Otherssegment totalrevenue2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-01-01 → 2023-03-31¥1.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-01-01 → 2023-03-31¥85m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 353
ItemContextValueUnit
Number of shares held in own name treasury shares etcCurrentQuarterInstant487100
Number of shares held in others names treasury shares etcCurrentQuarterInstant－
Total number of shares held treasury shares etcCurrentQuarterInstant487100
Shareholding ratio treasury shares etcCurrentQuarterInstant0.0097
Cash and depositsPrior1YearInstant5484000000JPY
Cash and depositsCurrentQuarterInstant5238000000JPY
Notes and accounts receivable tradePrior1YearInstant1985000000JPY
Notes and accounts receivable tradeCurrentQuarterInstant1935000000JPY
Merchandise and finished goodsPrior1YearInstant421000000JPY
Merchandise and finished goodsCurrentQuarterInstant417000000JPY
Work in processPrior1YearInstant387000000JPY
Work in processCurrentQuarterInstant538000000JPY
Raw materials and suppliesPrior1YearInstant565000000JPY
Raw materials and suppliesCurrentQuarterInstant517000000JPY
Other caPrior1YearInstant264000000JPY
Other caCurrentQuarterInstant116000000JPY
Current assetsPrior1YearInstant9109000000JPY
Current assetsCurrentQuarterInstant8764000000JPY
Buildings and structures netPrior1YearInstant1025000000JPY
Buildings and structures netCurrentQuarterInstant1003000000JPY
Machinery equipment and vehicles netPrior1YearInstant826000000JPY
Machinery equipment and vehicles netCurrentQuarterInstant794000000JPY
LandPrior1YearInstant1675000000JPY
LandCurrentQuarterInstant1675000000JPY
Construction in progressPrior1YearInstant2000000JPY
Construction in progressCurrentQuarterInstant20000000JPY
Other net ppePrior1YearInstant50000000JPY
Other net ppeCurrentQuarterInstant55000000JPY
Property plant and equipmentPrior1YearInstant3581000000JPY
Property plant and equipmentCurrentQuarterInstant3548000000JPY
Intangible assetsPrior1YearInstant1000000JPY
Intangible assetsCurrentQuarterInstant20000000JPY
Investment securitiesPrior1YearInstant236000000JPY
Investment securitiesCurrentQuarterInstant374000000JPY
Other ioaPrior1YearInstant291000000JPY
Other ioaCurrentQuarterInstant289000000JPY
Investments and other assetsPrior1YearInstant527000000JPY
Investments and other assetsCurrentQuarterInstant663000000JPY
Noncurrent assetsPrior1YearInstant4111000000JPY
Noncurrent assetsCurrentQuarterInstant4233000000JPY
AssetsPrior1YearInstant13220000000JPY
AssetsCurrentQuarterInstant12997000000JPY
Notes and accounts payable tradePrior1YearInstant375000000JPY
Notes and accounts payable tradeCurrentQuarterInstant338000000JPY
Current portion of long term loans payablePrior1YearInstant1206000000JPY
Current portion of long term loans payableCurrentQuarterInstant1276000000JPY
Accounts payable otherPrior1YearInstant740000000JPY
Accounts payable otherCurrentQuarterInstant519000000JPY
Income taxes payablePrior1YearInstant42000000JPY
Income taxes payableCurrentQuarterInstant29000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-12-31pass rounding
balance sheet identityconsolidated 2024-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-12-31pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net income attributable to parentconsolidated 2023-01-01/2023-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-01-01/2024-03-31pass
statement vs summary · revenueconsolidated 2023-01-01/2023-03-31pass
statement vs summary · revenueconsolidated 2024-01-01/2024-03-31pass
statement vs summary · total assetsconsolidated 2023-12-31pass
statement vs summary · total assetsconsolidated 2024-03-31pass